Improvement of Pulmonary Function by Oral Treatment with a VLA-4 Antagonist in a Mouse Asthmatic Model
-
- Takayama Gensuke
- Daiichi Sankyo Co., Ltd., Japan
-
- Matsumoto Keiko
- Daiichi Sankyo Co., Ltd., Japan
-
- Taira Tomoe
- Daiichi Sankyo Co., Ltd., Japan
-
- Aonuma Misato
- Daiichi Sankyo R&D Novare Co., Ltd., Japan
-
- Yokoyama Mika
- Daiichi Sankyo Co., Ltd., Japan
-
- Iigo Yutaka
- Daiichi Sankyo R&D Novare Co., Ltd., Japan
-
- Takashi Tohru
- Daiichi Sankyo R&D Novare Co., Ltd., Japan
Search this article
Abstract
We investigated in vivo efficacies of the newly synthesized VLA-4 antagonist Compound A {trans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4S)methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid} on Ascaris antigen–induced airway inflammation and hyperresponsiveness in a murine asthmatic model. Oral administration of Compound A significantly inhibited eosinophil infiltration into BALF and airway hyperresponsiveness 48 h after the antigen challenge. Histologic analysis of the lung sections confirmed the BALF result and revealed suppression of edema and mucus hyperplasia at 8 and 48 h after the challenge, respectively. These findings clearly show that orally active Compound A has therapeutic potential for treatment of asthma.
Journal
-
- Journal of Pharmacological Sciences
-
Journal of Pharmacological Sciences 121 (2), 172-175, 2013
The Japanese Pharmacological Society
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390001205181078656
-
- NII Article ID
- 10031156946
-
- NII Book ID
- AA11806667
-
- COI
- 1:CAS:528:DC%2BC3sXjvVyisrw%3D
-
- ISSN
- 13478648
- 13478613
-
- NDL BIB ID
- 024275138
-
- PubMed
- 23419271
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed